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See related article on page 340. Cardioplegia is used as a myoprotective agent for the alleviation ofsurgically induced ischemic injury, incurred during cardiac opera-tive procedures, to allow the functional preservation of the myo-cardium. These solutions allow for the rapid electromechanicalarrest of the myocardium through alteration of cellular electro-chemical gradients.1 Most cardioplegic solutions use a high potas-
sium content to arrest the heart.2 The use of hypothermic potassium cardioplegia in
adult cardiac surgery increases the safely available intraoperative time and has been
correlated with improved postischemic myocardial functional recovery and reduced
postoperative mortality.3
Potassium-induced arrest maintains the heart in a depolarized state, significantly
decreasing the energy demand of the myocardium, but basal metabolic energy
requirements are sustained and thus still constitute a significant energy expenditure.4
The advantages of cardioplegic arrest in providing a bloodless field are tempered by
the fact that depolarization also leads to the alteration of ion flux across the
sarcolemmal membrane and is associated with both increased cytosolic calcium
accumulation and the significant depletion of cellular high-energy (adenosine
triphosphate) reserves.5-9
The use of blood cardioplegia is currently the criterion standard with which all
cardioplegic formulations must be compared, and its benefits relative to crystalloid
cardioplegia have been extensively reported.10-13 Similarly, the relative contribu-
tions of hypothermia (cold, warm, and tepid cardioplegia) and the route of admin-
istration of cardioplegia (retrograde, antegrade, and combined retrograde and ante-
grade delivery) have been examined.14-18 The applicability of high-potassium
cardioplegia to the neonatal and immature heart remains poorly defined and will not
be addressed here, but the reader is directed to reviews by del Nido19 and Hammon20
and the recent reviews of Allen and colleagues21 and Ihnken22 for further information.
Despite continuous improvements in surgical technique and cardioplegic formu-
lations, the inadequacies of current intraoperative myocardial protection protocols
and formulations, most of which maintain as their basis high-potassium depolarizing
arrest, remain a concern. Novel myoprotective protocols to allow enhanced func-
tional recovery of the myocardium after ischemia and reperfusion continue to be
needed. In this issue of the Journal, Bessho and Chambers23 present evidence in
favor of the use of oxygenated multidose crystalloid esmolol cardioplegia to induce
cardiac arrest as an alternative to St Thomas’ Hospital cardioplegic solution No. 2.
Esmolol is an ultra–short acting (9-minute half-life) cardioselective -blocker
that is rapidly hydrolyzed by an esterase in the blood cell cytosol to an inactive form,
thus avoiding the negative inotropic and chronotropic effects of prolonged -block-
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ade. Bessho and Chambers23 present a well-designed set of
studies with appropriate controls to investigate the role of
oxygenation of crystalloid esmolol cardioplegia and the
effects of single and multidose delivery in providing en-
hanced cardioprotection in an isolated buffer-perfused rat
heart model of global ischemia and reperfusion. Compari-
sons with deoxygenated control solutions and with St
Thomas’ Hospital cardioplegic solution No. 2 are provided.
Bessho and Chambers23 also investigate the efficacy of
oxygenated multidose crystalloid esmolol cardioplegia in
providing cardioprotection after 60, 75, 90, and 120 minutes
of global ischemia and 60 minutes of reperfusion.
Intrinsic to the development of new myoprotective pro-
tocols for use in cardiac surgery is the requirement that
these protocols be as good as or better than traditional
cardioplegia in providing enhanced postischemic functional
recovery and myocellular preservation. In their article,
Bessho and Chambers23 show that the oxygenation of mul-
tidose crystalloid esmolol cardioplegia is essential to pro-
vide effective cardioprotection. They further show that mul-
tidose crystalloid esmolol cardioplegia must be delivered at
a constant pressure (45 mm Hg) rather than a constant flow.
They show—as evidenced by recovery of left ventricular
developed pressure, left ventricular end-diastolic pressure,
coronary flow, and heart rate—that delivery of oxygenated
multidose crystalloid esmolol cardioplegia at a constant
pressure provides complete myocardial protection for as
long as 90 minutes at 37°C and is superior to St Thomas’
Hospital cardioplegic solution No. 2.
The short half-life of esmolol (9 minutes) necessitates 3
minutes of infusion every 15 minutes at a constant pressure
of 45 mm Hg to maintain pharmacologic effectiveness,
however; this protocol is not significantly different from
current cardioplegic readministration protocols for intermit-
tent cardioplegia and provides for rapid cardiac arrest sim-
ilar to traditional cardioplegia. Bessho and Chambers32
speculate that the effects of esmolol cardioplegia include
enhanced balance of myocardial oxygen supply and demand
through the reduction of inotropic and chronotropic actions
and may be associated with increased blood flow to isch-
emic areas or the redistribution of blood flow from the
subepicardium to the subendocardium. They concede that
further studies with a larger animal model are needed for
determination of surgical relevance, as is investigation of
delivery routes, temperature, and applicability to neonatal,
immature, and aged patients. The current inability to deliver
esmolol in blood cardioplegia because of inactivation also
requires further study.
In this issue of the Journal, Bessho and Chambers23
present a well-designed study that closely examines a sur-
gically relevant issue in an experimental model. Although
the cardioprotective mechanisms remain to be elucidated,
the benefits of esmolol cardioplegia offer the potential to
provide a needed alternative to traditional high-potassium
depolarizing cardioplegia.
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